Destiny Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Destiny Pharma's estimated annual revenue is currently $5.3M per year.
- Destiny Pharma's estimated revenue per employee is $155,000
Employee Data
- Destiny Pharma has 34 Employees.
- Destiny Pharma grew their employee count by 0% last year.
Destiny Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CSO | Reveal Email/Phone |
Destiny Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Destiny Pharma?
Destiny Pharma plc is an established, clinical stage, innovative biotechnology company focused on the development of nobel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic resistant bacteria, often referred to as "superbugs". Our proprietary XF-series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling the drug-resistant bacteria that are at the centre of a global healthcare crisis.
keywords:N/A
N/A
Total Funding
34
Number of Employees
$5.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Destiny Pharma News
Destiny Pharma PLC (AIM:DEST) said its strengthened balance sheet provides it with the opportunity to take its two late-stage assets to value...
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-...
Destiny Pharma's 29021 year-end cash of £4.65mln together with a £6.5mln fundraise in March 2022 provides a funding runway into mid-2023,...
Other Companies in Brighton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.9M | 34 | -3% | N/A |
#2 | $9.6M | 34 | 3% | N/A |
#3 | $9.2M | 35 | 30% | N/A |
#4 | $4.2M | 35 | 0% | N/A |
#5 | $1.7M | 35 | 9% | N/A |